Catalyst Wire Dossier Catalyst Wire Dossier

Osemitamab

osemitamab · Suzhou Transcenta Therapeutics Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Osemitamab, covering 2025-12-17 to 2025-12-17. Get the full timeline:

Most recent: Clinical Trial Update: Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma [Phase 3]

See pricing